[HTML][HTML] Should Canadian patients look forward to aducanumab for Alzheimer disease?
• The recent approval of aducanumab by the US Food and Drug Administration was
controversial.• Both phase 3 trials for aducanumab were terminated for futility after a …
controversial.• Both phase 3 trials for aducanumab were terminated for futility after a …
Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee
GS Day, N Scarmeas, R Dubinsky, K Coerver… - Neurology, 2022 - AAN Enterprises
Objective To identify the class of evidence for aducanumab use for the treatment of
Alzheimer disease and present clinical considerations regarding use. Methods The author …
Alzheimer disease and present clinical considerations regarding use. Methods The author …
[PDF][PDF] Challenges with new treatments for Alzheimer disease: Accelerated approval of aducanumab in the United States raises questions
Background The manufacturer of aducanumab conducted 2 phase 3 placebo-controlled
randomized trials (EMERGE and ENGAGE) that included participants aged 50 to 85 years …
randomized trials (EMERGE and ENGAGE) that included participants aged 50 to 85 years …
Aducanumab: first approval
S Dhillon - Drugs, 2021 - Springer
Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1
(IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of …
(IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of …
Aducanumab for Alzheimer's disease: summarized data from EMERGE, ENGAGE, and PRIME studies
JM Yuksel, J Noviasky, S Britton - The Senior Care Pharmacist, 2022 - ingentaconnect.com
Objective To review the data informing the US Food and Drug Administration (FDA) approval
for aducanumab for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) …
for aducanumab for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) …
Questions EMERGE as Biogen claims aducanumab turnaround
R Howard, KY Liu - Nature Reviews Neurology, 2020 - nature.com
Trials of aducanumab in Alzheimer disease were previously discontinued following a phase
III futility analysis, but Biogen now says that additional data indicate that longer exposure to …
III futility analysis, but Biogen now says that additional data indicate that longer exposure to …
Accelerated approval of aducanumab: where do we stand now?
H Barenholtz Levy - Annals of Pharmacotherapy, 2022 - journals.sagepub.com
Aducanumab was approved by the Food and Drug Administration (FDA) in June 2021 to
treat Alzheimer disease (AD). Its path to approval has been highly scrutinized, with many …
treat Alzheimer disease (AD). Its path to approval has been highly scrutinized, with many …
[CITATION][C] Controversy and progress in Alzheimer's disease—FDA approval of aducanumab
GD Rabinovici - New England Journal of Medicine, 2021 - Mass Medical Soc
Controversy and Progress in Alzheimer's Disease The FDA's accelerated approval of
aducanumab represents a landmark moment, though the drug's road to the clinic has been …
aducanumab represents a landmark moment, though the drug's road to the clinic has been …
Aducanumab therapy to treat Alzheimer's disease: a narrative review
SA Beshir, AM Aadithsoorya, A Parveen… - International Journal …, 2022 - Wiley Online Library
Background. Aducanumab, a new monoclonal antibody that targets β‐amyloid aggregates,
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …
An insider's perspective on FDA approval of aducanumab
Y Wang - Alzheimer's & Dementia: Translational Research & …, 2023 - Wiley Online Library
Introduction Aducanumab was approved in 2021 by the US Food and Drug Administration
(FDA) under the accelerated approval pathway. Since then, there have been many …
(FDA) under the accelerated approval pathway. Since then, there have been many …
